Cargando…

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis

BACKGROUND AND PURPOSE: Beta‐interferons (IFNβ) are the most widely prescribed drugs for patients with multiple sclerosis (MS). However, whether or not treatment with IFNβ can delay secondary progressive MS (SPMS) onset remains unknown. Our aim was to examine the association between IFNβ exposure an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, T., Shirani, A., Zhao, Y., Karim, M. E., Gustafson, P., Petkau, J., Evans, C., Kingwell, E., van der Kop, M., Zhu, F., Oger, J., Tremlett, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008210/ https://www.ncbi.nlm.nih.gov/pubmed/25846809 http://dx.doi.org/10.1111/ene.12698

Ejemplares similares

Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment
por: Shirani, Afsaneh, et al.
Publicado: (2015)

Evaluating the safety of β-interferons in MS: A series of nested case-control studies
por: de Jong, Hilda J.I., et al.
Publicado: (2017)

Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study
por: Zhang, Tingting, et al.
Publicado: (2017)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

The effect of smoking on the symptoms and progression of multiple sclerosis: a review
por: Shirani, Afsaneh, et al.
Publicado: (2010)

Accurate classification of secondary progression in multiple sclerosis using a decision tree
por: Ramanujam, Ryan, et al.
Publicado: (2020)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Sex and age differences in the Multiple Sclerosis prodrome
por: Yusuf, Fardowsa L. A., et al.
Publicado: (2022)

A multiple sclerosis disease progression measure based on cumulative disability
por: Manouchehrinia, Ali, et al.
Publicado: (2021)

Neonatal and Delivery Outcomes in Women with Multiple Sclerosis
por: van der Kop, Mia L, et al.
Publicado: (2011)

Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study
por: Evans, Charity, et al.
Publicado: (2021)

A population‐based study comparing multiple sclerosis clinic users and non‐users in British Columbia, Canada
por: McKay, K. A., et al.
Publicado: (2016)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

‘Beta-interferons’ and ‘oligoclonal bands’ in multiple sclerosis in India
por: Hassan, K. M.
Publicado: (2011)

A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada
por: McKay, Kyla, et al.
Publicado: (2017)

Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
por: Gurevich, Michael, et al.
Publicado: (2015)

Disease-modifying drugs for multiple sclerosis and subsequent health service use
por: Ng, Huah Shin, et al.
Publicado: (2021)

A longitudinal model for disease progression was developed and applied to multiple sclerosis
por: Lawton, Michael, et al.
Publicado: (2015)

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis
por: Burkill, Sarah, et al.
Publicado: (2019)

Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
por: Elmazny, Alaa, et al.
Publicado: (2020)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
por: Jeannin, S., et al.
Publicado: (2011)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Malekzadeh, Masoud Mohammad, et al.
Publicado: (2020)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
por: Xavier, Alexandre, et al.
Publicado: (2023)

UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
por: Palace, Jacqueline, et al.
Publicado: (2014)

Age Related Multiple Sclerosis Severity Score: Disability ranked by age
por: Manouchehrinia, Ali, et al.
Publicado: (2017)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Jankovic, Slobodan M
Publicado: (2010)

Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review
por: McKay, Kyla A., et al.
Publicado: (2015)

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
por: Simone, Isabella Laura, et al.
Publicado: (2006)

Beta-interferons in multiple sclerosis: A single center experience in India
por: Gupta, Salil, et al.
Publicado: (2010)

Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
por: Marziniak, Martin, et al.
Publicado: (2014)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop, Florian, et al.
Publicado: (2013)

PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
por: Reuss, Reinhard
Publicado: (2013)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
por: Hyun, Jae-Won, et al.
Publicado: (2018)

Thrombotic microangiopathy associated with interferon-beta treatment in patients with multiple sclerosis
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2018)

The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis
por: Zhang, Tingting, et al.
Publicado: (2016)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_9s178a6d118dcocc12j7d150rc